P31 SINGLE-AGENT BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: FINAL ANALYSIS OF THE DREAMM-2 TRIAL - A. Nooka; A. Cohen; H. Lee; A. Badros; A. Suvannasankha; N. Callander; A. Abdallah; S. Trudel; A. Chari; E. Libby; M. Chaudhry; M. Hultcrantz; et al. (HemaSphere, 2023)